Komentarai Siųsti draugui Spausdinti Vertinimas Neįvertintas

GRD: “Grindeks” unveils manufacturing unit of ointments and gels

Spekuliantai.lt | 2012-11-28 | NASDAQ OMX biržų naujienos | perskaitė: 1243
Raktiniai žodžiai: Grindeks, GRD
GRD: “Grindeks” unveils manufacturing unit of ointments and gels

Grindeks Company Announcement 28.11.2012

“Grindeks” unveils manufacturing unit of ointments and gels

Today, on 28 November 2012, in Riga, 53 Krustils Street, JSC “Grindeks” has
solemnly unveiled a manufacturing unit of ointments and gels, which is one of
the most modern in the Baltic States and meets world-class standards of
pharmaceutical manufacturing. Altogether 2.5 million lats were invested in the
manufacturing unit of ointments and gels, out of which the co-financing of the
EU structural funds – 448.67 thousand lats. The investments are planned to be
recovered within 2 years.

The opening ceremony of the manufacturing unit of ointments and gels has been
attended by the Minister of Health of the Republic of Latvia Ingrīda Circene,
Chairman of the Council of “Grindeks” Kirovs Lipmans, Chairman of the Board of
“Grindeks” Juris Bundulis, Ambassador Extraordinary and Plenipotentiary of the
People`s Republic of China to the Republic of Latvia H.E. Hu Yeshun, Ambassador
Extraordinary and Plenipotentiary of the Republic of Belarus to Latvia H.E.
Aleksandr Gerasimenko and “Grindeks” cooperation partners.

Chairman of the Council of “Grindeks” Kirovs Lipmans: “The future of the
company cannot be imagined without investment and development projects! Today,
investing 2.5 million lats, we have successfully concluded another investment
project and we are unveiling a new manufacturing unit of ointments and gels.
Thanks to this investment, the company will increase its productivity and
production capacity. This will increase our competitiveness and in the near
future will allow complementing our product range with new ointments and gels.”

Chairman of the Board of “Grindeks” Juris Bundulis: “The development of
“Grindeks” is in the most direct way dependent on the policy of shareholders –
to invest in the company`s development. This project is another example of
“Grindeks” shareholders` interest in the the company`s sustainability. In the
centre of our operations is the patient, and the new, world-class manufacturing
unit of ointments and gels is an important incentive to find more and more
efficient solutions for patients` health improvement.”

The manufacturing unit of ointments and gels is equipped with modern and
high-powered technological devices that ensure convenient, safe, efficient and
environmentally friendly production. In October this year, the new
manufacturing unit received the Certificate of Good Manufacturing Practice from
the State Agency of Medicines of Latvia. The new manufacturing unit will be
able to produce up to 20 million tubes per year. In the new manufacturing unit
of ointments and gels of “Grindeks”, there are new job positions created for 10
qualified operators and technical engineering specialists. It is planned that
the new manufacturing unit will provide also medication manufacturing for other
companies according to their orders or to provide contract manufacturing
services.



About „Grindeks”

“Grindeks” is the leading pharmaceutical company in the Baltic States. Its main
fields of action are: research, development, manufacturing and sale of original
products, generics and active pharmaceutical ingredients. The Group of
“Grindeks” consists of four subsidiary companies in Latvia, Estonia and Russia,
as well representative offices in eleven countries.

“Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer
medication therapeutic groups. A range of products covers a successful
combination of original products and generics, with the original products
Mildronate® and Ftorafur® and more than 100 forms of effective and safe
generics included therein. Currently “Grindeks” produces 22 active
pharmaceutical ingredients.

Products of the company are exported to 50 countries and its export comprises
more than 95% of the total turnover. The main markets are: Russia and other CIS
countries, the Baltic States, Germany, the Netherlands, Japan and the U.S. In
2010 the Ministry of Economics of Republic of Latvia and the Investment and
Development Agency of Latvia awarded “Grindeks” as the most export potential
company of Latvia.

During the last years the company realized many considerable investment
projects in purpose to increase production capacity and develop infrastructure
and invested 32.7 million lats within five years.

JSC “Grindeks” shares are listed on the Official List of “NASDAQ OMX Riga”.
Major shareholders of JSC “Grindeks” are Kirovs Lipmans – 33.29%, Anna Lipmane
– 16.69%, “AB.LV Private Equity fund 2010” – 11.38%, “Skandinaviska Enskilda
Banken” (nominal holder) – 10.22%, “Swedbank” AS Clients Account (nominal
holder) – 8.58%.



More information about the company – www.grindeks.lv/en/

Follow “Grindeks”:

Twitter.com/AS_Grindeks; http://Youtube.com/GrindeksLV


Further information:

Laila Kļaviņa
Head of the Communications Department, JSC “Grindeks”
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
E-mail: [email protected]


Project “Construction of manufacturing unit of ointments and gels” is
co-funded by the European Regional Development Fund.


1. Fact_Sheet.pdf
(https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=411435)

Taip pat skaitykite

DPK: Decisions of the regular meeting of shareholders dated 27.05.2013

VLN: NEW MUTUAL FUND TO THE BALTIC FUND CENTER

VLN: The results of the primary placement auction of Lithuanian Government securities

VLN: VVP pirminio platinimo aukciono rezultatai

2013-05-27 | NASDAQ OMX biržų naujienos 2013-05-27 | NASDAQ OMX biržų naujienos 2013-05-27 | NASDAQ OMX biržų naujienos 2013-05-27 | NASDAQ OMX biržų naujienos

Komentarai



Ekonominis kalendorius

Prekybos statistika realiu laiku

Techninės analizės įrankis

Privatumo politika Reklama Kontaktai Paskolos RSS RSS
© 2006-2024 UAB All Media Digital